Anat Ashkenazi Net Worth

The estimated Net Worth of Anat Ashkenazi is at least $319 Thousand dollars as of 16 February 2021. Ms. Ashkenazi owns over 1,225 units of Varian Medical Systems stock worth over $42,561 and over the last 6 years she sold VAR stock worth over $0. In addition, she makes $276,809 as Independent Director at Varian Medical Systems.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Ashkenazi VAR stock SEC Form 4 insiders trading

Anat has made over 2 trades of the Varian Medical Systems stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 1,225 units of VAR stock worth $20,255 on 16 February 2021.

The largest trade she's ever made was exercising 1,349 units of Varian Medical Systems stock on 13 February 2020 worth over $22,306. On average, Anat trades about 184 units every 26 days since 2019. As of 16 February 2021 she still owns at least 2,574 units of Varian Medical Systems stock.

You can see the complete history of Ms. Ashkenazi stock trades at the bottom of the page.

Anat Ashkenazi biography

Anat Ashkenazi serves as Independent Director of the Company. ?Positions at Eli Lilly and Company, a global pharmaceutical company: • ?Senior Vice President, Controller and Chief Financial Officer, Lilly Research Labs (September 2016—present) • ?Vice President, Finance and Chief Financial Officer, Lilly Diabetes and Lilly Global Manufacturing and Quality (April 2015—September 2016) • ?Chief Financial Officer, Lilly Oncology (October 2013—April 2015)

What is the salary of Anat Ashkenazi?

As the Independent Director of Varian Medical Systems, the total compensation of Anat Ashkenazi at Varian Medical Systems is $276,809. There are 6 executives at Varian Medical Systems getting paid more, with Dow Wilson having the highest compensation of $9,446,300.

How old is Anat Ashkenazi?

Anat Ashkenazi is 47, she's been the Independent Director of Varian Medical Systems since 2018. There are 12 older and 1 younger executives at Varian Medical Systems. The oldest executive at Varian Medical Systems, Inc. is David Illingworth, 66, who is the Independent Director.

What's Anat Ashkenazi's mailing address?

Anat's mailing address filed with the SEC is C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO, CA, 92121.

Insiders trading at Varian Medical Systems

Over the last 21 years, insiders at Varian Medical Systems have traded over $57,574,967 worth of Varian Medical Systems stock and bought 500 units worth $22,595 . The most active insiders traders include Kent J Thiry, Timothy E Guertin, and Dow R Wilson. On average, Varian Medical Systems executives and independent directors trade stock every 11 days with the average trade being worth of $181,124. The most recent stock trade was executed by Jesse Michael Bruff on 1 March 2021, trading 6,499 units of VAR stock currently worth $1,142,589.

What does Varian Medical Systems do?

Complete history of Ms. Ashkenazi stock trades at Lilly(Eli) & Co, Varian Medical Systems, and Maravai Lifesciences

Varian Medical Systems executives and stock owners

Varian Medical Systems executives and other stock owners filed with the SEC include:

• Dow Wilson,
  Chief Executive Officer, Director
• Kolleen Kennedy,
  President - Proton Solutions Division and Chief Growth Officer
• Chris Toth,
  President, Chief Operating Officer
• R. Andrew Eckert,
  Independent Chairman of the Board
• Jeffrey Balser,
  Independent Director
• Judy Bruner,
  Independent Director
• Anat Ashkenazi,
  Independent Director
• Jean-Luc Butel,
  Independent Director
• Regina Dugan,
  Independent Director
• David Illingworth,
  Independent Director
• Phillip Febbo,
  Independent Director
• Michael Hutchinson,
  Senior Vice President, Chief Legal Officer
• Francis Facchini,
  President, Interventional Solutions Business
• Anshul Maheshwari,
  Vice President, Treasurer and Investor Relations
• Michelle Le Beau,
  Independent Director
• J. Michael Bruff,
  Chief Financial Officer, Senior Vice President - Finance
• Magnus Momsen,
  SVP, CAO, Corporate Controller
• Mark R Laret,
  Director
• Jose Baselga,
  Director
• John W Kuo,
  SVP, Gen Counsel and Secretary
• Gary E Jr Bischoping,
  SVP, Finance & CFO
• Susan L Bostrom,
  Director
• Timothy E Guertin,
  Director
• Clarence R Verhoef,
  SVP, Finance, Corp Controller
• Venkatraman Thyagarajan,
  Director
• Sunny Sanyal,
  SVP and President, ICB
• Robert H Kluge,
  Corporate Vice President
• Richard M Levy,
  President and CEO
• Ruediger Naumann Etienne,
  Director
• John Seely Brown,
  Director
• Erich R Reinhardt,
  Director
• Tai Yun Chen,
  VP and Corporate Controller
• David W Jr Martin,
  Director
• Steven A Leibel,
  Director
• Kent J Thiry,
  Director
• Allen S Lichter,
  Director
• Samuel Hellman,
  Director
• Crisanto C Raimundo,
  Corporate Controller
• Terry R Lautenbach,
  Director
• Joseph B Phair,
  VP Admin,Gen Counsel,Secretary
• Elisha W Finney,
  Corporate Vice President & CFO
• Kevin O'reilly,
  SVP, President of Oncology Sys